Bluebird Bio Inc. (NASDAQ:BLUE) has been given a $100.00 target price by Maxim Group in a research note issued on Thursday. The firm presently has a a “buy” rating on the stock. Maxim Group’s price target points to a potential upside of 47.54% from the company’s current price.
A number of other equities research analysts have also recently weighed in on the company. Jefferies Group reaffirmed a “buy” rating and set a $80.00 price target on shares of Bluebird Bio in a report on Friday, September 23rd. Roth Capital began coverage on Bluebird Bio in a report on Thursday, September 22nd. They set a “buy” rating and a $87.00 price target on the stock. Goldman Sachs Group Inc. raised Bluebird Bio from a “buy” rating to a “conviction-buy” rating and set a $135.00 price target on the stock in a report on Thursday, September 15th. BTIG Research reiterated a “buy” rating and set a $72.00 price objective on shares of Bluebird Bio in a research note on Sunday, September 11th. Finally, Cowen and Company reiterated an “outperform” rating on shares of Bluebird Bio in a research note on Friday, September 9th. Five investment analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company’s stock. Bluebird Bio presently has a consensus rating of “Buy” and a consensus target price of $90.25.
Bluebird Bio (NASDAQ:BLUE) opened at 67.78 on Thursday. The firm’s 50 day moving average price is $59.90 and its 200-day moving average price is $49.20. The stock’s market cap is $2.52 billion. Bluebird Bio has a 52 week low of $35.37 and a 52 week high of $106.95.
Bluebird Bio (NASDAQ:BLUE) last released its quarterly earnings results on Wednesday, August 3rd. The company reported ($1.59) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.44) by $0.15. The business had revenue of $1.55 million for the quarter, compared to the consensus estimate of $2.01 million. Bluebird Bio had a negative net margin of 3,512.13% and a negative return on equity of 24.85%. The business’s quarterly revenue was down 68.6% on a year-over-year basis. During the same period last year, the firm posted ($1.57) EPS. Analysts expect that Bluebird Bio will post ($6.18) EPS for the current year.
In related news, insider David Davidson sold 1,000 shares of the firm’s stock in a transaction that occurred on Friday, July 15th. The shares were sold at an average price of $45.08, for a total value of $45,080.00. Following the completion of the transaction, the insider now owns 10,600 shares of the company’s stock, valued at approximately $477,848. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Eric Sullivan sold 2,807 shares of the firm’s stock in a transaction that occurred on Wednesday, July 20th. The stock was sold at an average price of $45.04, for a total transaction of $126,427.28. Following the completion of the transaction, the insider now directly owns 4,656 shares of the company’s stock, valued at approximately $209,706.24. The disclosure for this sale can be found here. 3.50% of the stock is currently owned by corporate insiders.
A number of institutional investors have recently bought and sold shares of BLUE. Seven Eight Capital LLC purchased a new position in Bluebird Bio during the first quarter worth approximately $108,000. Quantbot Technologies LP raised its position in Bluebird Bio by 431.3% in the second quarter. Quantbot Technologies LP now owns 2,848 shares of the company’s stock worth $123,000 after buying an additional 2,312 shares in the last quarter. Legal & General Group Plc raised its position in Bluebird Bio by 31.6% in the first quarter. Legal & General Group Plc now owns 2,895 shares of the company’s stock worth $123,000 after buying an additional 695 shares in the last quarter. Amalgamated Bank purchased a new position in Bluebird Bio during the second quarter worth approximately $222,000. Finally, National Planning Corp purchased a new position in Bluebird Bio during the second quarter worth approximately $246,000.
Bluebird Bio Company Profile
bluebird bio, Inc is a biotechnology company. The Company is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell-based immunotherapy. Its gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia (TDT) and severe sickle cell disease (SCD), and Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD), a rare hereditary neurological disorder.
Receive News & Ratings for Bluebird Bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bluebird Bio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.